On June 30, 2023, PERRIGO COMPANY ($NYSE:PRGO) reported its second quarter earnings results for FY2023. Total revenue for the quarter was USD 1193.1 million, showing a 6.4% increase from the same quarter in the prior year. Net income for the quarter was USD 8.4 million, demonstrating a 112.9% year over year increase.
On Tuesday, PERRIGO COMPANY reported strong second quarter earnings for its fiscal year 2023. The stock opened at $38.1 and closed at $39.9, a rise of 8.5% from its prior closing price of 36.8. The strong earnings report gave investors confidence in the company’s ability to continue to perform well.
This impressive earnings report indicates that the company is on track for a successful year. The strong second quarter results have further bolstered the confidence of investors in the company’s ability to continue to deliver strong financial performance going forward. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Perrigo Company. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Perrigo Company. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Perrigo Company. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Perrigo Company are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Perrigo Company Intrinsic Stock Value
GoodWhale recently conducted an analysis of PERRIGO COMPANY‘s wellbeing. According to our proprietary Valuation Line, the fair value of PERRIGO COMPANY share is around $53.7, while the stock is currently trading at $39.9. This means that PERRIGO COMPANY’s stock is undervalued by 25.6%. We believe that the stock has potential to reach or even surpass the fair value in the long run and is certainly worth looking at closely. More…
Risk Rating Analysis
Star Chart Analysis
Yuhan Corp, JW Pharmaceutical and Lavipharm SA are all competitors of Perrigo Co PLC.
Yuhan Corp is a South Korean conglomerate that operates in the pharmaceutical and chemical industries. It has a market cap of 3.83T as of 2022 and a Return on Equity of 4.29%. The company was founded in 1926 and is headquartered in Seoul. It is one of the largest companies in South Korea and is a major player in the global pharmaceutical market.
As of 2022, JW Pharmaceutical has a market cap of 396.36B and a Return on Equity of 13.04%. The company is a global pharmaceutical company that develops, manufactures, and markets prescription and over-the-counter medicines.
PERRIGO COMPANY had a strong second quarter of FY2023. Total revenue was up 6.4% year-over-year, and net income rose by an impressive 112.9%. As a result, the company’s stock price moved up on June 30, 2023.
Investors may want to consider PERRIGO COMPANY as a potential investment since the company has seen strong growth over the past quarter, and has the potential to continue growing in the future. It is important for investors to research the industry and company fundamentals to assess whether PERRIGO COMPANY is a good fit for their portfolio.